Citadel Advisors’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Citadel Advisors’s Portfolio ENZN Stock Details ENZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-29,174	Closed	-$28K	–	9598
2015 Q3	$28K	Sell	29,174 -25,173	-46%	-$31K	﹤0.01%	7984
2015 Q2	$65K	Buy	+54,347	New	+$69.2K	﹤0.01%	7476
2014 Q4	–	Sell	-23,379	Closed	-$25K	–	8947
2014 Q3	$25K	Buy	+23,379	New	+$28.9K	﹤0.01%	7313
2014 Q2	–	Sell	-562,822	Closed	-$579K	–	8589
2014 Q1	$579K	Buy	562,822 +435,573	+342%	+$450K	﹤0.01%	4138
2013 Q4	$148K	Sell	127,249 -125,252	-50%	-$193K	﹤0.01%	5300
2013 Q3	$425K	Buy	252,501 +157,272	+165%	+$291K	﹤0.01%	3973
2013 Q2	$190K	Buy	+95,229	New	+$279K	﹤0.01%	4719

Other funds holding ENZN

Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SCP

Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citadel Advisors's ENZN Position: Q4 2015 in Review

Citadel Advisors sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2015, closing a stake of 29,174 shares — an estimated $28K sold.

Citadel Advisors first reported a position in ENZN in Q2 2013 and held it in 7 quarters. The position peaked at $579K in Q1 2014. 49 funds tracked by Wall St. Rank hold ENZN as of Q4 2015.

Citadel Advisors reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2015 after selling out during the quarter.
Citadel Advisors sold 29,174 ENZON PHARMACEUTICALS INC shares in Q4 2015, an estimated $28K.
Citadel Advisors first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 7 quarters.
Citadel Advisors's ENZON PHARMACEUTICALS INC position peaked at $579K in Q1 2014.
49 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2015.

Based on Citadel Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.